[IrishExaminer] The HSE [Health Service Executive} has admitted a greater risk of blood clotting in younger people still exists for the AstraZeneca vaccine, but that risk is now outweighed by a need to speed up public vaccination.
A new modelling study
| ...oh lord, more models. Anybody have any idea how good —or bad — this one is? Based on similar models, Dr. Anthony Fauci, et al predicted Covid-19 would be a 1918 Flu event, or worse.... |
published in the European Centre for Disease Prevention and Control’s (ECDC) medical journal has concluded that the dangers presented to younger people by the AstraZeneca vaccine are greater than the benefits.
| The HSE said that the risk of rare blood clotting from Astrazeneca and Janssen, known as adenoviral vector vaccines, is one per 100,000 for those aged over 50, and double that, or two per 100,000 for those aged younger than 50. |
However, the HSE has now said that the offer of an AstraZeneca or Johnson & Johnson jab to the younger cohort is purely voluntary.
"If someone aged 18 to 34 would prefer to get their vaccine at a HSE vaccination centre, they can wait and register online later this month," a spokesperson said. In the case of those who choose to opt for the AstraZeneca or Janssen shots, "getting either of these vaccines will mean they will be vaccinated earlier", they said, than if they wait to get the Pfizer or Moderna vaccine.
The HSE said that the risk of rare blood clotting from Astrazeneca and Janssen, known as adenoviral vector vaccines, is one per 100,000 for those aged over 50, and double that, or two per 100,000 for those aged younger than 50.
| And they know how to treat, or at least ameliorate, blood clotting, right? That suggests that the riskiness of the risk is even lower than that. But the risks from other Covid-19 vaccines are even lower for the under-50s at risk from the Astrazeneca and Janssen vaccines, so as far as I can see this falls under nice to know but no need to worry. |
That rare clotting, known as Thrombocytopenia Syndrome (TTS), has a case fatality rate of between 17% and 20%, it said. |